Prot #FLX925-01: Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects with Relapsed or Refractory Acute Myeloid Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date3/16/16 → 3/16/19

Funding

  • Medpace, Inc. (Prot #FLX925-01 // Prot #FLX925-01)
  • FLX Bio, Inc. (Prot #FLX925-01 // Prot #FLX925-01)